š Up to 70% Off Selected ItemsShop Sale




Banoriv 20 mg 28 Tablets
Banoriv 20mg 28 Tablets contains Rivaroxaban 20 mg, an anticoagulant that helps prevent and treat blood clots by blocking Factor Xa, a key clotting factor in the blood.
Benefits:
- Helps prevent stroke in patients with non-valvular atrial fibrillation.
- Used to treat deep vein thrombosis (DVT).
- Used to treat pulmonary embolism (PE).
- Helps prevent the recurrence of blood clots.
- Reduces the blood's tendency to form harmful clots.
Main Ingredient:
Rivaroxaban 20 mg: An anticoagulant that helps prevent the formation of blood clots.
Benefits:
- Helps prevent stroke in patients with non-valvular atrial fibrillation.
- Used to treat deep vein thrombosis (DVT).
- Used to treat pulmonary embolism (PE).
- Helps prevent the recurrence of blood clots.
- Reduces the blood's tendency to form harmful clots.
Main Ingredient:
Rivaroxaban 20 mg: An anticoagulant that helps prevent the formation of blood clots.
$5.07
Original: $14.48
-65%Banoriv 20 mg 28 Tabletsā
$14.48
$5.07Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Banoriv 20mg 28 Tablets contains Rivaroxaban 20 mg, an anticoagulant that helps prevent and treat blood clots by blocking Factor Xa, a key clotting factor in the blood.
Benefits:
- Helps prevent stroke in patients with non-valvular atrial fibrillation.
- Used to treat deep vein thrombosis (DVT).
- Used to treat pulmonary embolism (PE).
- Helps prevent the recurrence of blood clots.
- Reduces the blood's tendency to form harmful clots.
Main Ingredient:
Rivaroxaban 20 mg: An anticoagulant that helps prevent the formation of blood clots.
Benefits:
- Helps prevent stroke in patients with non-valvular atrial fibrillation.
- Used to treat deep vein thrombosis (DVT).
- Used to treat pulmonary embolism (PE).
- Helps prevent the recurrence of blood clots.
- Reduces the blood's tendency to form harmful clots.
Main Ingredient:
Rivaroxaban 20 mg: An anticoagulant that helps prevent the formation of blood clots.



















